The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Addressing infectious diseases in Africa by accelerating drug discovery through data science
Communications Medicine Open Access 25 November 2025
-
Mycobacterial biotin synthases require an auxiliary protein to convert dethiobiotin into biotin
Nature Communications Open Access 16 May 2024
-
A spotlight on the tuberculosis epidemic in South Africa
Nature Communications Open Access 12 February 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Conradie, F. et al. N. Engl. J. Med. 382, 893–902 (2020).
Early, J. et al. ACS Infect. Dis. 5, 272–280 (2019).
VanderVen, B. C. et al. PLoS Pathog. 11, e1004679 (2015).
Warrier, T. et al. ACS Infect. Dis. 1, 580–585 (2015).
Kim, J. H. et al. Proc. Natl Acad. Sci. USA 110, 19095–19100 (2013).
Ballinger, E. et al. Science 363, eaau8959 (2019).
Blanc, L. et al. eLife 7, e41115 (2018).
Tasneen, R. et al. Antimicrob. Agents Chemother. 60, 270–277 (2016).
Via, L. E. et al. ACS Infect. Dis. 1, 203–214 (2015).
Prideaux, B. et al. Nat. Med. 21, 1223–1227 (2015).
Sarathy, J. P. et al. ACS Infect. Dis. 2, 552–563 (2016).
Strydom, N. et al. PLoS Med. 16, e1002773 (2019).
Chakraborty, S., Gruber, T., Barry, C. E. III, Boshoff, H. I. & Rhee, K. Y. Science 339, 88–91 (2013).
Wang, Z. et al. Proc. Natl Acad. Sci. USA 116, 19646–19651 (2019).
Cokol, M., Kuru, N., Bicak, E., Larkins-Ford, J. & Aldridge, B. B. Sci. Adv. 3, e1701881 (2017).
Ballell, L. et al. ChemMedChem 8, 313–321 (2013).
Diacon, A. H. et al. N. Engl. J. Med. 375, 393–394 (2016).
Aggarwal, A. et al. Cell 170, 249–259.e225 (2017).
Ray, P. C. et al. ACS Omega 6, 2284–2311 (2021).
Chengalroyen, M. D. et al. Front. Cell. Infect. Microbiol. 10, 582416 (2020).
Xu, J. et al. Antimicrob. Agents Chemother. 65, e02418 (2021).
Tiwari, D. et al. Sci. Transl. Med. 10, eaal1803 (2018).
Evans, J. C. et al. ACS Infect. Dis. 2, 958–968 (2016).
Beites, T. et al. Nat. Commun. 10, 4970 (2019).
Berube, B.J. et al. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.02661-18 (2019).
Smith, J. et al. Medchemcomm 10, 934–945 (2019).
Park, Y. et al. ACS Infect. Dis. 3, 18–33 (2017).
Marakalala, M. J. et al. Nat. Med. 22, 531–538 (2016).
Cox, J. A. et al. New Microbiol. 1, 15006 (2016).
Wang, Q. et al. Science 367, 1147–1151 (2020).
Author information
Authors and Affiliations
Contributions
C.E.B., R.H.B., S.J.B., K.D., N.F., V.M., C.N., B.R. and P.W. served as the drafting committee; C.E.B. prepared the figure with assistance from B.B.A., H.I.B., V.D., K.D., K.Y.R. and J.C.S.; and D.B.-A., K.C., X.-J.C., C.B.C., F.G., P.A.H., D.J.., J.L., A.J.L., C.W.M., D.B.O., T.P., H.M.P., A.P., G.T.R., J.M.R., E.J.R., D.G.R., D.S., M.S., A.M.U., P.G.W. and Y.Y. contributed comments.
Corresponding author
Ethics declarations
Competing interests
D.B.-A., R.H.B. and J.L. are employed by GlaxoSmithKline; F.G. is employed by Eisai; P.A.H. is employed by Lgenia; D.J.K. and M.S. are employed by AbbVie; D.B.O. is employed by Merck & Co.; H.M.P. is employed by Calibr; A.P. is employed by Janssen-Cilag; and A.M.U. is employed by Evotec.
Rights and permissions
About this article
Cite this article
Aldridge, B.B., Barros-Aguirre, D., Barry, C.E. et al. The Tuberculosis Drug Accelerator at year 10: what have we learned?. Nat Med 27, 1333–1337 (2021). https://doi.org/10.1038/s41591-021-01442-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-021-01442-2
This article is cited by
-
A low-toxicity linezolid analog has potential for use in all patients with tuberculosis
Nature Medicine (2026)
-
Addressing infectious diseases in Africa by accelerating drug discovery through data science
Communications Medicine (2025)
-
Mycobacterium tuberculosis biology, pathogenicity and interaction with the host
Nature Reviews Microbiology (2025)
-
Strategies for shortening tuberculosis therapy
Nature Medicine (2025)
-
Mycobacterial biotin synthases require an auxiliary protein to convert dethiobiotin into biotin
Nature Communications (2024)
